Insilico Medicine

Insilico Medicine is a global clinical-stage biotechnology company powered by generative AI, connecting biology, chemistry and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that use deep generative models, reinforcement learning, transformers and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases and ageing-related diseases.

The company was founded in 2014 by Alex Zhavoronkov and is privately owned.